Opus Genetics Announces Positive Low Dose Cohort 1 Data from Phase 1/2 Clinical Trial of OPGx-BEST1 and Successful FDA Type C Meeting with Potential Phase 3 Dosing in 2027
Stocks in this Quantisnow insightHealth Care
Quantisnow market dataNASDAQ
IRD
Opus Genetics Inc.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
Get push alerts for IRD
Full IRD profile on Quantisnow Follow IRD and get a push notification the moment its next story breaks.